SCHEMBL6501082

SCHEMBL6501082

Cc1cc(C(=O)O)nc2c1nc(C)n2Cc1ccc(-c2ccco2)cc1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CB P42338 2/20 0.40
KDM4E B2RXH2 3/20 0.38
ALDH1A1 P00352 3/20 0.38
MAPT P10636 3/20 0.38
MEN1 O00255 2/20 0.38
POLB P06746 2/20 0.38
GAA P10253 2/20 0.38
PKM P14618 2/20 0.38
KMT2A Q03164 2/20 0.38
APEX1 P27695 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
RCE1 Q9Y256 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
HPGD P15428 2/20 0.37
TP53 P04637 1/20 0.37
ALOX15 P16050 1/20 0.37
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37
CASP1 P29466 1/20 0.37
CASP7 P55210 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6503451 0.90 HPGD (0.44) PIK3CBKDM4EALDH1A1MAPTMEN1
SCHEMBL6299864 0.86 PIK3CB (0.41) PIK3CBALDH1A1MAPT
SCHEMBL6503942 0.86 ALDH1A1 (0.39) KDM4EALDH1A1MAPTMEN1POLB
SCHEMBL6502289 0.84 PTGS2 (0.39) KDM4EALDH1A1MAPTHPGD
SCHEMBL6493908 0.83 PPARG (0.46) MAPTUSP7
SCHEMBL6491464 0.82 PPARG (0.49) USP7
SCHEMBL6307128 0.81 PIK3CB (0.38) PIK3CBKDM4EALDH1A1MAPTHPGD
SCHEMBL6299430 0.80 PIK3CB (0.39) PIK3CBALDH1A1MAPTPIK3C2B
SCHEMBL6300801 0.80 PIK3CB (0.40) PIK3CBALDH1A1MAPTPIK3C2B
SCHEMBL6301216 0.79 PIK3CB (0.42) PIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6890934-B2 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-05-10 US disclosed
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-09-11 US disclosed
US-6573274-B1 Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-06-03 US disclosed
EP-1136492-A1 SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines PDE2A, PDE3A, PDE5A PIK3CB 1729/4885KDM4E 1599/4885ALDH1A1 476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.